Magnetic resonance imaging contrast agents: Overview and perspectives

被引:156
作者
Yan, Guo-Ping [1 ,2 ]
Robinson, Leslie [3 ]
Hogg, Peter [3 ]
机构
[1] Wuhan Inst Technol, Sch Mat Sci & Engn, 693 Xiongchu Rd, Wuhan 430073, Hubei Province, Peoples R China
[2] Queensland Univ Technol, Sch Phys & Chem Sci, Brisbane, Qld 4001, Australia
[3] Univ Salford, Sch Hlth Care Profess, Manchester M6 6PU, Lancs, England
基金
澳大利亚研究理事会;
关键词
Magnetic resonance imaging (MRI); Contrast agents; Paramagnetic; Superparamagnetic; Gadolinium(III); Tissue or organ-targeting;
D O I
10.1016/j.radi.2006.07.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Magnetic resonance imaging (MRI) is a non-invasive clinical imaging modality, which has become widely used in the diagnosis and/or staging of human diseases around the world. Some MRI examinations include the use of contrast agents. The categorizations of currently available contrast agents have been described according to their effect on the image, magnetic behavior and biodistribution in the body, respectively. In this field, superparamagnetic iron oxide particles and soluble paramagnetic metal chelates are two main classes of contrast agents for MRI. This review outlines the research and development of MRI contrast agents. In future, the ideal MRI contrast agent will be focused on the neutral tissue-or organ-targeting materials with high relaxivity and specificity, low toxicity and side effects, suitable long intravascular duration and excretion time, high contrast enhancement with low dose in vivo, and with minimal cost. (C) 2006 The College of Radiographers. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E5 / E19
页数:15
相关论文
共 171 条
  • [11] Andre JP, 1999, CHEM-EUR J, V5, P2977, DOI 10.1002/(SICI)1521-3765(19991001)5:10<2977::AID-CHEM2977>3.0.CO
  • [12] 2-T
  • [13] Conjugates of gadolinium complexes to bile acids as hepatocyte-directed contrast agents for magnetic resonance Imaging
    Anelli, PL
    Lattuada, L
    Lorusso, V
    Lux, G
    Morisetti, A
    Morosini, P
    Serleti, M
    Uggeri, F
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) : 3629 - 3641
  • [14] Anelli PL, 1996, GAZZ CHIM ITAL, V126, P89
  • [15] MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles
    Artemov, D
    Mori, N
    Okollie, B
    Bhujwalla, ZM
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2003, 49 (03) : 403 - 408
  • [16] Molecular magnetic resonance imaging with targeted contrast agents
    Artemov, D
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 90 (03) : 518 - 524
  • [17] Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan®, (NC100150) for MRI of renal perfusion:: Experimental study in an animal model
    Bachmann, R
    Conrad, R
    Kreft, B
    Luzar, O
    Block, W
    Flacke, S
    Pauleit, D
    Träber, F
    Gieseke, J
    Saebo, K
    Schild, H
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2002, 16 (02) : 190 - 195
  • [18] Bai ZW, 1996, ION EXCHANGE ADSORPT, V12, P332
  • [19] Bai ZW, 1997, CHINESE J MAGNETIC R, V14, P347
  • [20] MR molecular imaging of early endothelial activation in focal ischemia
    Barber, PA
    Foniok, T
    Kirk, D
    Buchan, AM
    Laurent, S
    Boutry, S
    Muller, RN
    Hoyte, L
    Tomanek, B
    Tuor, UI
    [J]. ANNALS OF NEUROLOGY, 2004, 56 (01) : 116 - 120